» Articles » PMID: 8783390

Chronic Lithium Attenuates Dopamine D1-receptor Mediated Increases in Acetylcholine Release in Rat Frontal Cortex

Overview
Specialty Pharmacology
Date 1996 May 1
PMID 8783390
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of chronic lithium treatment on methylphenidate-, D1 dopamine receptor agonist (A-77636)-, and tactile stimulation-induced increases in frontal cortical acetylcholine release were studied in the rat using in vivo brain microdialysis. Cortical acetylcholine release in control rats was maximally stimulated by methylphenidate (1.25 and 2.5 mg/kg) to 173% and 212% above baseline, respectively. The effect of methylphenidate (2.5 mg/kg) was blocked by pretreatment with the dopamine D1 receptor antagonist SCH 23390 (0.3 mg/kg). Chronic treatment with lithium chloride (3-4 weeks) produced plasma lithium concentrations of 0.45 +/- 0.02 meq/l. Chronic lithium significantly reduced increases in cortical acetylcholine release produced by methylphenidate. Stimulation of dopamine D1 receptors with the full D1 receptor agonist A-77636 (0.73 mg/kg) increased cortical acetylcholine release. Chronic lithium significantly reduced this effect of A-77636. In contrast, lithium failed to influence the increases of cortical acetylcholine release produced by tactile stimulation. These results suggest that while lithium does not influence normal, arousal-related increase in cortical acetylcholine release, this ion selectively attenuates dopamine mediated increases and/or abnormally large increases, which in the present circumstances were pharmacologically induced. The relevance of these findings to the antimanic actions of lithium is discussed.

Citing Articles

Dopamine D1-like receptor blockade and stimulation decreases operant responding for nicotine and food in male and female rats.

Chellian R, Behnood-Rod A, Wilson R, Lin K, King G, Ruppert-Gomez M Sci Rep. 2022; 12(1):14131.

PMID: 35986048 PMC: 9388990. DOI: 10.1038/s41598-022-18081-3.


PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Stevens T, Sangkuhl K, Brown J, Altman R, Klein T Pharmacogenet Genomics. 2019; 29(6):136-154.

PMID: 30950912 PMC: 6581573. DOI: 10.1097/FPC.0000000000000376.


3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Nair S, Gudelsky G Psychopharmacology (Berl). 2005; 184(2):182-9.

PMID: 16378215 DOI: 10.1007/s00213-005-0271-5.


Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear.

Acquas E, Wilson C, Fibiger H J Neurosci. 1996; 16(9):3089-96.

PMID: 8622138 PMC: 6579062.

References
1.
Casamenti F, Deffenu G, Abbamondi A, Pepeu G . Changes in cortical acetylcholine output induced by modulation of the nucleus basalis. Brain Res Bull. 1986; 16(5):689-95. DOI: 10.1016/0361-9230(86)90140-1. View

2.
Wood A, Goodwin G, de Souza R, Green A . The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology. 1986; 25(11):1285-8. DOI: 10.1016/0028-3908(86)90149-8. View

3.
Chou J . Recent advances in treatment of acute mania. J Clin Psychopharmacol. 1991; 11(1):3-21. View

4.
Acquas E, Day J, Fibiger H . The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat. Eur J Pharmacol. 1994; 260(1):85-7. DOI: 10.1016/0014-2999(94)90013-2. View

5.
Inglis F, Fibiger H . Increases in hippocampal and frontal cortical acetylcholine release associated with presentation of sensory stimuli. Neuroscience. 1995; 66(1):81-6. DOI: 10.1016/0306-4522(94)00578-s. View